Novo Nordisk A/S - Share repurchase programme
Bagsværd, Denmark, 8 July 2019 – On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.
Under the programme initiated 7 May 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 8 May 2019 to 7 August 2019.
Since the announcement as of 1 July 2019, the following transactions have been made under the programme:
|Accumulated, last announcement||4,468,000||1,464,295,863|
|1 July 2019||125,000||339.31||42,413,255|
|2 July 2019||128,000||342.91||43,892,487|
|3 July 2019||140,500||346.88||48,736,153|
|4 July 2019||135,900||342.54||46,551,012|
|5 July 2019||125,000||339.80||42,474,713|
|Accumulated under the programme||5,122,400||1,688,363,483|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 27,465,543 B shares of DKK 0.20, corresponding to 1.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 5 July 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 20,298,904 B shares at an average share price of DKK 326.29 per B share equal to a transaction value of DKK 6,623,317,084.
|Anne Margrethe Hauge||+45 4442 email@example.com|
|Ken Inchausti (US)||+1 609 240 firstname.lastname@example.org|
|Peter Hugreffe Ankersen||+45 3075 email@example.com|
|Valdemar Borum Svarrer||+45 3079 firstname.lastname@example.org|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com|
|Kristoffer Due Berg (US)||+1 609 235 firstname.lastname@example.org|
Company announcement 40/2019
Upcoming Life Sciences Events
- November 2019
- Duesseldorf: DxPx Conference 2019
- Krakow: Life Science Open Space 2019
- December 2019
- London: The Pharma Licensing Negotiation Course